Accelrys Announces Fourth Quarter and Full Year 2011 Financial Results
SAN DIEGO– Accelrys, Inc. (NASDAQ:ACCL) today reported financial results for the quarter and full year ended December 31, 2011. Non-GAAP revenue for the quarter ended December 31, 2011 decreased $1.6 million to $40.8 million from $42.5 million for the same quarter of the previous year, or a decrease of 4%. Non-GAAP revenue for the year ended December 31, 2011 increased $30.3 million to $155.0 million from $124.7 million for the 12 months ended December 31, 2010, or an increase of 24%.
Non-GAAP net income was $4.6 million, or $0.08 per diluted share, for the quarter ended December 31, 2011 compared to non-GAAP net income of $4.3 million, or $0.08 per diluted share, for the same quarter of the previous year. Non-GAAP net income was $19.0 million, or $0.34 per diluted share, for the year ended December 31, 2011 compared to non-GAAP net income of $10.6 million, or $0.25 per diluted share, for the 12 months ended December 31, 2010.
Non-GAAP free cash flow was $7.9 million for the quarter ended December 31, 2011 compared to non-GAAP free cash flow of $5.7 million for the same quarter of the previous year. Non-GAAP free cash flow more than doubled to $33.2 million for the year ended December 31, 2011 when compared to non-GAAP free cash flow of $15.5 million for the 12 months ended December 31, 2010.
The GAAP results for the quarter and year ended December 31, 2011 were impacted by the business combination accounting associated with the acquisitions of Contur Industry Holding AB and Contur Software AB (collectively, “Contur”) and VelQuest Corporation (“VelQuest”) in 2011 and the merger with Symyx Technologies in 2010, and by other nonrecurring acquisition-related and restructuring costs. GAAP revenue, GAAP operating loss, other income and GAAP net income for the quarter and year ended December 31, 2011 were negatively impacted by fair value adjustments to both deferred revenue ($1.1 million and $10.7 million, respectively) and deferred royalty income ($0.2 million and $0.8 million, respectively). GAAP operating income for those periods was also negatively impacted by business consolidation, transaction and restructuring costs ($1.5 million and $7.8 million, respectively), stock-based compensation expense ($1.4 million and $5.6 million, respectively) and purchased intangible asset amortization ($4.6 million and $18.2 million, respectively), while GAAP net income for the same periods was negatively impacted by additional purchased intangible asset amortization ($0.6 million and $2.4 million, respectively). In addition, GAAP net income was positively impacted by the net gain recognized upon the sale of our equity investment in Intermolecular ($19.0 million in both periods), offset by the write off of the associated intangible assets ($4.3 million in both periods).
GAAP revenue for the quarter ended December 31, 2011 increased $8.4 million to $39.8 million from $31.3 million for the same quarter of the previous year, or an increase of 27%. GAAP revenue for the year ended December 31, 2011 increased $43.4 million to $144.3 million from $101.0 million for the 12 months ended December 31, 2010, or an increase of 43%.
GAAP net income was $14.2 million or $0.25 per diluted share, for the current quarter compared to GAAP net loss of $15.6 million, or $0.28 per diluted share, for the same quarter of the previous year. GAAP net income was $1.8 million or $0.03 per diluted share, for the year ended December 31, 2011 compared to GAAP net loss of $23.0 million, or $0.55 per diluted share, for the 12 months ended December 31, 2010.
“2011 was an important year for Accelrys, one in which we established our operational baseline following the merger with Symyx Technologies in the prior year. I am pleased with the progress we made in all areas of the business, completing our integration activities and significant releases in all of our core product lines,” said Max Carnecchia, President and CEO. “We also completed two key acquisitions that further our strategy of assisting companies optimize their product innovation cycle, bringing products from lab to market more quickly and efficiently and at a lower cost. We have built a solid foundation from which we will continue to serve our customers and grow our business organically and through further acquisitions in 2012.”
Recent Business Highlights:
• Announced our Company strategy and supporting enterprise architecture, enabling industries and organizations that rely on scientific innovation to bring new products from lab to market more quickly and efficiently.
• Completed two acquisitions furthering our strategy of optimizing the research and development value chain. Contur, an emerging leader in cost-effective Electronic Laboratory Notebooks (“ELN”), expanded the range of ELN offerings and added Software-as-a-Service capabilities. VelQuest, the leading provider of paperless lab execution systems, extended the portfolio into the downstream pharmaceutical Quality Assurance and Quality Control space.
• Delivered new product releases with important capabilities in each of the core product lines across the four portfolio segments, including:
o New biotherapeutics capabilities in Discovery Studio and state-of-the-art capabilities in predictive materials development in Materials Studio (Modeling and Simulation);
o New formulations capabilities in Symyx Notebook by Accelrys and integrated with Pipeline Pilot for data analytics and reporting, as well as access to the rich library of chemistry and biology components. (Enterprise Lab Management and Workflow Automation & Analytics);
o New, unified Cheminformatics Suite with a new Web-based chemical registration system (Informatics);
o Enhanced scalability, security and deployment capabilities of the Enterprise R&D Platform to optimize support for global scientific enterprises (Platform)
2012 Objectives
• Return to organic orders and revenue growth.
• Continue to invest in key areas of the portfolio, as well as make investments in the field organization that align with our Company strategy.
• Complete additional acquisitions with a focus on adding capabilities that strengthen our position downstream in Development and Quality Assurance and Quality Control, drive growth in business outside life sciences, and expand the business further in the biology scientific domain.
Calendar Year 2012 Outlook
For the year ending December 31, 2012, the Company expects non-GAAP revenue to be between $164 and $170 million, and non-GAAP diluted earnings per share to be between $0.32 and $0.34 per diluted share on fully diluted weighted average shares outstanding of 56 million and using an effective tax rate of 40%.
Non-GAAP Financial Measures:
This press release describes financial measures for revenue, operating income, net income, net income per diluted share and free cash flow that exclude deferred revenue fair value adjustments, stock-based compensation expense, purchased intangible asset amortization, business consolidation, transaction and restructuring costs, gain on sale of equity investment, sale of intangible asset, royalty income fair value adjustments and income tax adjustments. These financial measures are not calculated in accordance with generally accepted accounting principles (GAAP) and are not based on any comprehensive set of accounting rules or principles.
Management believes these non-GAAP financial measures provide a useful measure of the Company’s operating results, a meaningful comparison with historical results and with the results of other companies, and insight into the Company’s ongoing operating performance. Further, management and the Board of Directors utilize these measures, in addition to GAAP measures, when evaluating and comparing the Company’s operating performance against internal financial forecasts and budgets. These non-GAAP financial measures should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. In addition, these non-GAAP financial measures may be different from non-GAAP financial measures used by other companies.
For additional information on the items excluded by the Company from its non-GAAP financial measures please refer to the Form 8-K regarding this release that was furnished today to the Securities and Exchange Commission.
The following table contains a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP financial measures (unaudited, amounts in thousands, except per share amounts, including footnotes):
Three Months Ended Year Ended
December 31, December 31,
2011 2010 2011 2010
GAAP Revenue $ 39,762 $31,330 $ 144,339 $ 100,964
Deferred revenue fair value adjustment1 1,081 11,137 10,652 23,698
Non-GAAP Revenue $ 40,843 $ 42,467 $ 154,991 $ 124,662
GAAP Operating loss $ (2,926) $(14,388) $(19,701) $(38,587)
Deferred revenue fair value adjustment1 1,081 11,137 10,652 23,698
Business consolidation, transaction
and restructuring cost2 1,538 4,449 7,772 16,320
Stock-based compensation expense3 1,424 787 5,572 5,315
Purchased intangible asset amortization4 4,638 3,829 18,239 7,640
Non-GAAP Operating income $ 5,755 $ 5,814 $ 22,534 $ 14,386
Non-GAAP Operating income $ 5,755 $ 5,814 $ 22,534 $ 14,386
Depreciation expense 923 854 3,800 2,479
Cash received for interest and royalty income 2,269 996 9,574 2,273
Cash (paid) for income taxes, net of refunds received (153) (20) 1,182 (276)
Capital expenditures (934) (1,934) (3,908) (3,350)
Non-GAAP Free cash flow 7,860 5,710 33,182 15,512
GAAP Net income (loss) $ 14,205 $(15,647) $1,765 $(22,982)
Deferred revenue fair value adjustment1 1,081 11,137 10,652 23,698
Business consolidation, transaction
and restructuring costs 2 1,538 4,449 7,772 16,320
Stock-based compensation expense3 1,424 787 5,572 5,315
Purchased intangible asset amortization4 5,230 4,452 20,604 8,886
Royalty income fair value adjustment5 200 204 803 408
Gain on sale of equity investment7 (18,970) - (18,970) -
Sale of intangible asset8 4,303 - 4,303 -
Income tax6 (4,456) (1,052) (13,454) (21,019)
Non-GAAP Net income $ 4,555 $ 4,330 $ 19,047 $ 10,626
GAAP Diluted net income (loss) per share $ 0.25 $ (0.28) $ 0.03 $ (0.55)
Deferred revenue fair value adjustment1 0.02 0.20 0.19 0.56
Business consolidation, transaction
and restructuring costs 2 0.03 0.08 0.14 0.39
Stock-based compensation expense3 0.03 0.01 0.10 0.13
Purchased intangible asset amortization4 0.09 0.08 0.37 0.21
Royalty income fair value adjustment5 - - 0.01 0.01
Gain on sale of equity investment7 (0.34 ) - (0.34) -
Sale of intangible asset8 0.08 - 0.08 -
Income tax6 (0.08 ) (0.02) (0.24) (0.50
Non-GAAP Diluted net income per share9 $ 0.08 $ 0.08 $ 0.34 $ 0.25
Weighted average shares used to compute net income (loss) per share
Basic 55,587 55,732 55,489 41,823
Diluted 55,933 56,583 56,037 42,317
1 Deferred revenue fair value adjustment relates to our merger with Symyx and acquisition of Contur, and adds back the impact of writing down the acquired historical deferred revenue to fair value as required by purchase accounting guidance.
2 Business consolidation, transaction and restructuring costs are included in the business consolidation, transaction and restructuring costs line in our consolidated statements of operations and consist of accounting, legal, and other fees incurred in connection with our acquisition activities, including our merger with Symyx and acquisitions of Contur and VelQuest, as well as integration costs incurred incurred in connection with such transactions, including consultant and employee related costs incurred during integration and transition periods. Also included are contingent compensation costs relating to the Contur acquisition as well as lease obligation exit costs, facility closure costs and severance and other related costs incurred in connection with the various restructuring activities commenced by the Company.
3 Stock-based compensation expense is included in our consolidated statements of operations as follows:
Three Months Ended Year Ended
December 31, December 31,
2011 2010 2011 2010
Cost of revenue $ 117 $76 $ 333 $ 257
Product development 313 251 1,136 1,019
Sales and marketing 362 260 1,672 1,228
General and administrative 620 525 2,428 1,932
Business consolidation, transaction
and restructuring costs 12 (325) 3 879
Total stock-based compensation expense $ 1,424 $ 787 $ 5,572 $ 5,315
4 Purchased intangible asset amortization is included in our consolidated statements of operations as follows:
Three Months Ended Year Ended
December 31, December 31,
2011 2010 2011 2010
Amortization of completed technology $ 2,135 $ 2,473 $ 8,393 $ 4,928
Purchased intangible asset amortization 2,503 1,356 9,846 2,712
Royalty and other income, net 592 623 2,365 1,246
Total purchased intangible amortization expense $ 5,230 $4,452 $ 20,604 $ 8,886
5 Royalty income fair value adjustment relates to our merger with Symyx, and adds back the impact of writing down deferred royalty income to fair value as required by purchase accounting guidance.
6 Income tax adjustments relate to adjusting our non-GAAP operating results to reflect an effective tax rate of 40% that would be applied if the Company was in a taxable income position and was not able to utilize its net operating loss carryforwards. The income tax adjustment also excludes any impact of a release of our valuation allowance against deferred tax assets. We have restated prior year amounts to include this income tax adjustment to conform to current period presentation.
7 Gain on sale of equity investment reflects the gain recognized upon the sale of our investment in Intermolecular in November 2011.
8 Sale of intangible asset reflects the write off of our cost basis in the intellectual property sold to Intermolecular in November 2011.
9 Earnings per share amounts for the three and twelve months ended December 31, 2010 do not add due to rounding.
About Accelrys:
Accelrys (NASDAQ:ACCL), a leading scientific enterprise R&D software and services company, supports industries and organizations that rely on scientific innovation to differentiate themselves. Accelrys' Enterprise Research & Development Architecture, built on the industry-leading Pipeline Pilot™ platform, provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow definition and capture, data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.
Headquartered in San Diego, Calif., Accelrys has more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries and employs approximately 150 full-time Ph.D. scientists. For more information about Accelrys, visit www.accelrys.com.
